In the past week, EYPT stock has gone down by -16.40%, with a monthly decline of -16.32% and a quarterly plunge of -0.05%. The volatility ratio for the week is 10.75%, and the volatility levels for the last 30 days are 10.03% for EyePoint Pharmaceuticals Inc The simple moving average for the last 20 days is -17.06% for EYPT stock, with a simple moving average of -34.15% for the last 200 days.
Is It Worth Investing in EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Right Now?
Additionally, the 36-month beta value for EYPT is 1.52. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for EYPT is 47.25M and currently, short sellers hold a 20.49% ratio of that float. The average trading volume of EYPT on November 20, 2024 was 747.49K shares.
EYPT) stock’s latest price update
The stock of EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has decreased by -2.33 when compared to last closing price of 9.21. Despite this, the company has experienced a -16.40% fall in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-14 that EyePoint Pharmaceuticals’ lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME, with one phase 3 trial ongoing and one more planned for 2025. EYP-1901 demonstrated strong safety, and efficacy, and reduced treatment burden, positioning it as a potential long-term solution for retinal diseases. Despite a failed NPDR trial, positive DME data suggest potential for targeting more severe diabetic retinopathy, enhancing the investment thesis.
Analysts’ Opinion of EYPT
Jefferies, on the other hand, stated in their research note that they expect to see EYPT reach a price target of $15. The rating they have provided for EYPT stocks is “Buy” according to the report published on August 28th, 2024.
JP Morgan gave a rating of “Overweight” to EYPT, setting the target price at $35 in the report published on January 22nd of the current year.
EYPT Trading at -8.05% from the 50-Day Moving Average
After a stumble in the market that brought EYPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.97% of loss for the given period.
Volatility was left at 10.03%, however, over the last 30 days, the volatility rate increased by 10.75%, as shares sank -9.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.49% upper at present.
During the last 5 trading sessions, EYPT fell by -16.36%, which changed the moving average for the period of 200-days by -68.83% in comparison to the 20-day moving average, which settled at $10.85. In addition, EyePoint Pharmaceuticals Inc saw -61.08% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EYPT starting from ANTHONY P. ADAMIS, who proposed sale 67,100 shares at the price of $10.04 back on Oct 23 ’24. After this action, ANTHONY P. ADAMIS now owns shares of EyePoint Pharmaceuticals Inc, valued at $673,355 using the latest closing price.
David R. Guyer, the Former Director of EyePoint Pharmaceuticals Inc, proposed sale 36,975 shares at $8.92 during a trade that took place back on Oct 14 ’24, which means that David R. Guyer is holding shares at $329,817 based on the most recent closing price.
Stock Fundamentals for EYPT
Current profitability levels for the company are sitting at:
- -2.56 for the present operating margin
- 0.91 for the gross margin
The net margin for EyePoint Pharmaceuticals Inc stands at -2.27. The total capital return value is set at -0.46. Equity return is now at value -74.68, with -44.94 for asset returns.
Based on EyePoint Pharmaceuticals Inc (EYPT), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -5.18.
Currently, EBITDA for the company is -69.0 million with net debt to EBITDA at 0.57. When we switch over and look at the enterprise to sales, we see a ratio of 12.29. The receivables turnover for the company is 120.93for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.50.
Conclusion
In conclusion, EyePoint Pharmaceuticals Inc (EYPT) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
